Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 19, 2025 07:00 ET | Source: OKYO Pharma LTD

OKYO Pharma to Ring the Opening Bell at Nasdaq

LONDON and NEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company which is developing urcosimod to treat neuropathic corneal pain...
December 15, 2025 08:30 ET | Source: OKYO Pharma LTD

OKYO Pharma Announces Chairman and Founder Acquires Shares

LONDON and NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic...
December 11, 2025 08:30 ET | Source: OKYO Pharma LTD

OKYO Pharma Announces New Data Showing Favorable Corneal Nerve Outcomes in Phase 2 Study for Neuropathic Corneal Pain

Patients treated with 0.05% urcosimod demonstrated directionally favorable improvements in nerve fiber count and fiber length, trends not observed in the placebo groupThese findings suggest that...
December 03, 2025 07:00 ET | Source: OKYO Pharma LTD

OKYO Pharma Announces Chairman and Founder Acquires Shares

LONDON and NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic...
November 21, 2025 08:30 ET | Source: OKYO Pharma LTD

OKYO Pharma Announces Chairman and Founder Acquires Shares

LONDON and NEW YORK, Nov. 21, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic...
November 18, 2025 08:30 ET | Source: OKYO Pharma LTD

OKYO Pharma to Present at OIS XV in San Diego

LONDON and NEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic...
October 29, 2025 07:00 ET | Source: OKYO Pharma LTD

OKYO Pharma to Present at BIO-Europe 2025 in Vienna

LONDON and NEW YORK, Oct. 29, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic...
October 16, 2025 08:30 ET | Source: OKYO Pharma LTD

OKYO Pharma Announces Chairman and Founder Acquires Shares

LONDON and NEW YORK, Oct. 16, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic...
September 22, 2025 08:30 ET | Source: OKYO Pharma LTD

OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain

LONDON and NEW YORK, Sept. 22, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic...
July 17, 2025 09:00 ET | Source: OKYO Pharma LTD

OKYO Pharma Receives $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal Pain

LONDON and NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic...